Ryxel

healthcare News

Biogen exceeds estimates as Alzheimer's drug growth offsets MS decline
Healthcare
1mo ago

Biogen exceeds estimates as Alzheimer's drug growth offsets MS decline

FY26 guidance of $15.25-$16.25 beats analyst consensus on cost-cutting and LEQEMBI momentum

Ocular Therapeutix cash runway fuels $24.25 target amid AXPAXLI trial
Healthcare
1mo ago

Ocular Therapeutix cash runway fuels $24.25 target amid AXPAXLI trial

Revenue declines to $13.3M but $737.1M balance supports operations through 2028

Embecta beats earnings estimates on strong international growth
Healthcare
1mo ago

Embecta beats earnings estimates on strong international growth

Diabetes care company maintains FY26 guidance despite 7.6% U.S. revenue decline

AbbVie Raises 2026 Outlook as Botox Sales Rebound
Healthcare
1mo ago

AbbVie Raises 2026 Outlook as Botox Sales Rebound

Pharmaceutical giant beats quarterly earnings with 13% growth in aesthetic treatments

AbbVie rallies on earnings beat, bullish 2026 outlook
Healthcare
1mo ago

AbbVie rallies on earnings beat, bullish 2026 outlook

Pharmaceutical giant raises full-year guidance as immunology drugs Skyrizi and Rinvoq drive growth

Azenta shares plunge 6% on earnings miss, margin deterioration
Healthcare
1mo ago

Azenta shares plunge 6% on earnings miss, margin deterioration

Life sciences company maintains turnaround guidance despite gross margin declining 380 basis points

Eli Lilly surges after smashing Q4 estimates, raising 2026 guidance
Healthcare
1mo ago

Eli Lilly surges after smashing Q4 estimates, raising 2026 guidance

Strong Mounjaro and Zepbound sales drive 43% revenue growth to $19.3B, well above analyst expectations

Aytu BioPharma falls as EXXUA launch burns cash despite revenue beat
Healthcare
1mo ago

Aytu BioPharma falls as EXXUA launch burns cash despite revenue beat

Heavy marketing investments and derivative liability losses drive $10.6M quarterly net loss, sending shares lower